The university marked a 10-year high for spinout generation and revealed its portfolio had cumulatively lured $452m in funding.

IP Group was among the investors for UPenn-founded cancer immunotherapy developer Carisma Therapeutics, which has now raised nearly $109m altogether.

UPMC Enterprise has returned for a $72m series B round raised by Werewolf Therapeutics, which is now set to advance two lead assets through phase 1 trials.

Osage University Partners has contributed to an $80m round for Dice Molecules, which is advancing Stanford University research and is also backed by Sanofi and Alexandria.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

CWRU‘s pain neurostimulation spinout has secured series BB funding ahead of a 180-patient trial.

Biopolymer material decontamination company Karamedica and genomic sequencing provider Murrieta Genomics have both joined UC Riverside's newly-launched Life Sciences Incubator.

Dalhousie's innovation and industry partnership office has a new moniker following a strategic review aimed at streamlining its processes.

Oxford Immunotec is set to return to private ownership in a $591m acquisition deal.

IP Group portfolio company Hinge Health has pushed its valuation to $3bn following a $300m series D round co-led by Coatue Management and Tiger Global.